Understand the source comparison
SS-LUP-332 Muscle Atrophy Prevention: Comparison
How does SS-LUP-332 muscle atrophy prevention compare to other interventions used to preserve muscle mass during disuse, illness, or caloric restriction? The following table contrasts mechanism, evidence base, and practical limitations. SLU-PP-332 (ERRα/γ agon
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- How does SS-LUP-332 muscle atrophy prevention compare to other interventions used to preserve muscle mass during disuse, illness, or caloric restriction? The following table contrasts mechanism, evidence base, and practical limitations.
- SLU-PP-332 (ERRα/γ agonist)
- Activates mitochondrial biogenesis and oxidative metabolism; reduces proteolytic signaling (FoxO/atrogenes)
- Rodent models: 30–50% reduction in disuse atrophy (hindlimb suspension). No human data.
- No human safety or efficacy data. Oral bioavailability and dosing schedule unknown. Research-grade only.
- Most mechanistically novel. Targets upstream metabolic cause rather than protein balance. High potential if human translation succeeds.
- Testosterone / Anabolic Steroids
- Androgen receptor activation increases mTOR signaling and protein synthesis
- Established efficacy in hypogonadal patients and cachexia (HIV, cancer). 2–5 kg lean mass gain over 12 weeks at therapeutic doses.
- Requires caloric surplus and mechanical load for maximal effect. Significant side effects: cardiovascular risk, HPTA suppression, virilization.
- Proven anabolic but systemically risky. Does not prevent atrophy during immobilization or fasting without adequate nutrition and loading.
- Protein Supplementation (1.6–2.2 g/kg)
- Provides substrate (amino acids) for protein synthesis; leucine activates mTOR
- Effective when combined with resistance training. Minimal benefit during bed rest or severe illness when proteolysis exceeds synthesis.
- Does not address the upstream signaling that activates muscle breakdown. Ineffective during immobilization or cachexia without mechanical stimulus.
- Necessary but insufficient. Fixes supply-side; ignores demand-side collapse in oxidative metabolism.
- BPC-157
- Proposed mechanisms: angiogenesis, nitric oxide modulation, growth factor upregulation
- Rodent studies show accelerated healing in tendon/ligament injury. Limited muscle atrophy data. Mechanism poorly defined.
- No Phase II/III human trials. Dosing, bioavailability, and safety profile unclear. Regulatory status ambiguous.
- Promising for soft tissue repair but weak evidence base for muscle preservation during disuse.
- Resistance Training (if feasible)
- Mechanical tension activates mTOR, inhibits FoxO, increases satellite cell recruitment
- Gold standard for muscle hypertrophy and maintenance. Effective across all populations with mobility.
- Impossible during immobilization, severe illness, or post-surgical recovery. Requires energy surplus for hypertrophy.
- Most effective intervention when possible. But context-dependent. SLU-PP-332 targets scenarios where training is not an option.